Full data for cabozantinib against liver cancer published in NEJM

5 July 2018

French biotech Ipsen (Euronext: IPN) has published full results from the Phase III CELESTIAL trial of cabozantinib, as a second-line treatment against advanced hepatocellular carcinoma (HCC). Originally presented at ASCO GI in January 2018, the data are now published in the New England Journal of Medicine (NEJM).

The results show that the trial met its primary endpoint, as cabozantinib provided a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo.

Ipsen and USA-based partner Exelixis (Nasdaq: EXEL) have agreed a collaboration to develop and commercialize the therapy, with Exelixis taking the USA, Takeda Pharmaceutical gaining rights in Japan and Ipsen taking the rest of the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK